Intracellular phosphorylation-modified peptides, processed and presented by MHC-I molecules on cancer cells and specifically recognized by CD8 T-cells, emerge as a novel class of neoantigens for immunotherapeutic targeting [102,103,104]. Here, CD8A is linked to cancer.